Home
Home

prostate cancer

Amgen: Xgeva panel review scheduled for February

Amgen: Xgeva panel review scheduled for February
Yahoo/AP

Dendreon: Where Do Things Stand On Provenge Reimbursement?

Dendreon: Where Do Things Stand On Provenge Reimbursement?
Seeking Alpha

Dendreon 2011: Supply Constrained to Missed Guidance

Dendreon 2011: Supply Constrained to Missed Guidance
Motley Fool

Prostate Cancer Drugs Aren’t Tied to Heart Attacks, Study Says

Prostate Cancer Drugs Aren’t Tied to Heart Attacks, Study Says
Bloomberg Businessweek

Medivation Back to Neutral

Medivation Back to Neutral
Yahoo/Zacks

Celgene Halts Prostate-Cancer Study for Top-Selling Revlimid

Celgene Halts Prostate-Cancer Study for Top-Selling Revlimid
Bloomberg

Time decay is key to Exelixis strategy

Time decay is key to Exelixis strategy
Yahoo/optionMONSTER

Dendreon: Medicare will cover more Provenge costs

Dendreon: Medicare will cover more Provenge costs
Yahoo/AP

Dendreon: New Trial To Examine Understatement Of Provenge Life-Extension Benefits

Dendreon: New Trial To Examine Understatement Of Provenge Life-Extension Benefits
Seeking Alpha
Submitted by moderatorj on Thu, 11/17/2011 - 23:36

Isoray: Impressive 98% Success Treating Prostate Cancer

Isoray: Impressive 98% Success Treating Prostate Cancer
Seeking Alpha